Stay updated on Tulisokibart Efficacy Safety Ulcerative Colitis Clinical Trial
Sign up to get notified when there's something new on the Tulisokibart Efficacy Safety Ulcerative Colitis Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2Fznb3k_Jn9XGz2kCqOj6GsXWkArU.uncropped.jpg&w=3840&q=75)
Latest updates to the Tulisokibart Efficacy Safety Ulcerative Colitis Clinical Trial page
- CheckyesterdayChange DetectedThe website has been updated from version 2.10.2 to 2.10.3, indicating a new release.SummaryDifference0.0%
- Check8 days agoChange DetectedNew study sites have been added in multiple locations including Bellevue, Washington; Guangzhou and Nanjing in China; Zagreb, Croatia; Tokyo, Japan; Amsterdam, Netherlands; and Ankara, Turkey, while a previous study site has been removed.SummaryDifference2%
- Check15 days agoChange DetectedThe study has expanded to include new recruiting sites in multiple countries, notably adding locations in Italy, China, and Japan, while removing previous sites in Japan and Taiwan.SummaryDifference3%
- Check22 days agoChange DetectedThe study has expanded to include 152 locations, with new sites added in Argentina, China, Greece, Israel, Italy, and Portugal, while some previous locations and contact numbers have been removed.SummaryDifference2%
- Check29 days agoChange DetectedThe study has increased from 136 to 144 participants, with new recruiting sites added in China, Greece, Italy, Japan, Poland, and Portugal, while the Tokyo site has been removed.SummaryDifference5%
- Check36 days agoChange DetectedThe study has added several new recruiting sites in China, Greece, Japan, the Netherlands, and Taiwan, increasing the total number of sites from 128 to 136, with the latest update posted on July 30, 2024.SummaryDifference2%
Stay in the know with updates to Tulisokibart Efficacy Safety Ulcerative Colitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tulisokibart Efficacy Safety Ulcerative Colitis Clinical Trial page.